ClinicalTrials.gg
CompletedNCT01023399Updated Feb 23, 2015

Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire

A Phase 4 interventional study of Artesunate + Amodiaquine in Malaria, sponsored by Sanofi. Completed at 1 site in Côte D'Ivoire. Per ClinicalTrials.gov, last updated 2015-02-23.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
580
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies testing artesunate in Malaria — none open to participants now, none under way, none of them phase 3. Artesunate · Malaria.

Enrollment
22nd of 66
580 · median 290
Started
2009
the only one that year
Phase 4
27 of 68
none open now
Registered
37th of 68
by date
Lead sponsor
6 of 68
Sanofi

Among the 68 studies testing artesunate in Malaria, this one is the 22nd largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2009, is one of 27 in phase 4, and was the 37th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

None of the 68 studies testing artesunate in Malaria is open now. The open studies under Malaria, anywhere →

About artesunate

Artesunate: first FDA approval 2020 (ARTESUNATE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 68 studies testing artesunate in Malaria as a file.
02

Study summary

The primary objective of this study is to demonstrate the non-inferiority of Polymerase Chain Reaction (PCR)-adjusted adequate clinical and parasitological response to artesunate plus amodiaquine at Day 28 in two groups of patients treated at the beginning of an artesunate plus amodiaquine implementation program and 24 months later.

The secondary objectives are Clinical and biological tolerability Evolution of gametocyte carriage Proportion of patients without fever at Day 3 Proportion of patients without parasite at Day 3 Treatment compliance Impact of implementation on anemia Measure of parasite sensibility to amodiaquine

03

Conditions studied

  • Malaria

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Body weight >=5kg
  • Plasmodium falciparum infection with parasite density > 2000/µL
  • Fever or history of fever
  • Able to be treated by oral route
  • No signs of severe malaria
  • No known allergy to study drugs
  • No other severe illnesses or underlying diseases
  • No known pregnancy or negative urinary pregnancy test for women of child bearing age
  • No participation in another ongoing clinical study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
580 participants (actual)

Study arms

  • Experimental
    Artesunate + Amodiaquine

    Oral fixed combination of artesunate (AS) and amodiaquine (AQ) Once daily, dose according to age Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister) Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister) Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister) Adults: \>= 14 years: AS 100/AQ 270 mg (6 tablets/ blister) 3 day-treatment

    Drug: Artesunate + Amodiaquine

Interventions

  • DrugArtesunate + Amodiaquine

    Drug pages: Artesunate · Amodiaquine

    Artesunate + Amodiaquine fixed dose combination

06

What researchers measure

Primary outcomes

  1. Polymerase chain reaction (PCR)-corrected and uncorrected clinical and parasitological cure rate (ACPR)

    Time frame: Day 28

Secondary outcomes

  1. Number of patients without fever

    Time frame: Day 3

  2. Number of patients without parasite

    Time frame: Day 3

  3. Number of gametocytes

    Time frame: Day 3, Day 7, Day 14, Day 21 and Day 28

  4. Evolution of in vitro resistance rate

    Time frame: Day 3, Day 7, Day 14, Day 21 and Day 28

07

Study locations

1 site
  • Investigational Site Number 1
    Agboville district, Côte D'Ivoire
08

References and documents

Publications

  • Assi SB, Nguessan AF, Aba YT, Toure AO, Menan H, Yavo JC, San KM, Bissagnene E, Duparc S, Lameyre V, Tanoh MA. Sustained Effectiveness of a Fixed-Dose Combination of Artesunate and Amodiaquine in 480 Patients with Uncomplicated Plasmodium falciparum Malaria in Cote d'Ivoire. Malar Res Treat. 2017;2017:3958765. doi: 10.1155/2017/3958765. Epub 2017 Dec 7. PubMed 29362685 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2009
First posted
Dec 2, 2009
Start
Nov 2009
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Last update
Feb 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01023399
Lead sponsor
Sanofi
Collaborators
Medicines for Malaria Venture
Responsible party
Sponsor
First posted
Dec 2, 2009
Start date
Nov 2009
Primary completion
Oct 2013
Completion
Oct 2013
Last update
Feb 23, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Artesunate · Amodiaquine

Start the discussion